4FE5EDE2-7790-4A75-9BB6-93260A8154A0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.939553219448094
- age_years
- 22
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.516
- E2F_TARGETS+0.502
- G2M_CHECKPOINT+0.441
- CHOLESTEROL_HOMEOSTASIS+0.432
- OXIDATIVE_PHOSPHORYLATION+0.417
- MYC_TARGETS_V2+0.415
- WNT_BETA_CATENIN_SIGNALING+0.384
- NOTCH_SIGNALING+0.377
- DNA_REPAIR+0.375
- PROTEIN_SECRETION+0.365
Top 10 suppressed
- KRAS_SIGNALING_DN-0.307
- SPERMATOGENESIS-0.171
- APICAL_SURFACE-0.101
- PANCREAS_BETA_CELLS-0.099
- MYOGENESIS-0.088
- BILE_ACID_METABOLISM-0.065
- INFLAMMATORY_RESPONSE-0.063
- ALLOGRAFT_REJECTION-0.029
- ESTROGEN_RESPONSE_LATE-0.005
- COAGULATION+0.008
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 569BCFB6-7B4D-459A-962A-4C148889CE2C | — | — | 0.929 |
| 2 | 5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4 | — | — | 0.929 |
| 3 | AABDF22D-9C2A-4994-A2D7-5167F23DDF36 | — | — | 0.927 |
| 4 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.926 |
| 5 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.925 |
| 6 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.924 |
| 7 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.923 |
| 8 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.920 |
| 9 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.918 |
| 10 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.516 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.502 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.441 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.432 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.417 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.415 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.384 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.377 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.375 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.365 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.357 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.357 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.325 | Inavolisib | — uncovered |
| APOPTOSIS | 0.315 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.286 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.277 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.274 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.271 | Remibrutinib | — uncovered |